Arecor featured by the highly regarded industry publication, Scrip - now available for viewing on the Arecor website

Arecor Limited, the specialty pharmaceutical company leveraging its innovative and proprietary formulation technology to develop superior treatments for a range of disease areas, including diabetes, is pleased to announce that a feature profile by the highly regarded industry publication, SCRIP, is now available on the news section of the company’s website via the following link: http://arecor.com/news/

This excellent feature came out shortly after the Company announced that it had filed a Clinical Trial Application (“CTA”) to conduct a Phase I study in Diabetes Type 1 patients of its ultra-rapid acting insulin product, AT247. This novel formulation of prandial insulin is designed to deliver an acceleration of insulin absorption post injection and the filing represents a key and important milestone in the advancement of the Company’s proprietary portfolio for diabetes care.

For more information, please contact:

Dr Sarah Howell
Arecor Limited
Chief Executive officer
Tel: +44 (0) 1223 426060
Email: sarah.howell@arecor.com

Mr Tarquin Edwards
Peckwater PR
Mob: +44 (0) 7879 458 364
Email: tarquin.edwards@peckwaterpr.co.uk

About Arecor (www.arecor.com)
Arecor Limited is a leader in developing superior biopharmaceuticals through the application of an innovative formulation technology platform. Arecor is leveraging this platform to develop a portfolio of proprietary products that will enable improved treatments for diabetes via the innovative reformulation of approved proteins and peptides. Arecor's product portfolio also includes:
• Novel insulin formulations to deliver ultra-rapid acting insulin analogs and;
• Ultra-concentrated rapid acting insulin to enable the miniaturisation of devices,
• Stable aqueous glucagon for emergency and artificial pancreas use, and
• A series of undisclosed pre-clinical programmes.

In addition, Arecor partners with leading pharmaceutical and biotech companies to deliver superior reformulations of their proprietary products, which would otherwise not be possible using conventional formulation science.

About ArestatTM
Arecor has significant experience and a proven track record in applying the ArestatTM formulation technology platform to deliver superior biopharmaceutical product profiles across a broad range of proteins, peptides and vaccines.

About Arecor’s Patent Portfolio
Arecor’s technology is protected by 28 patent families, including 26 granted patents. Arecor has been exploiting its technology in partnerships with pharmaceutical companies, successfully developing superior product profiles, including stable high-concentration antibodies with low viscosity, reformulations of lyophilised or freeze-dried products into stable liquids or stable vaccines that can be used outside the cold chain.